Written Exposure Therapy + Ketamine for Post-Traumatic Stress Disorder
Trial Summary
What is the purpose of this trial?
This trial combines writing therapy and ketamine injections to help people with chronic PTSD who don't fully benefit from current treatments. Ketamine makes the brain more adaptable, and writing about trauma helps reduce its emotional impact. Ketamine has shown benefits for treating PTSD symptoms and is being explored in combination with psychotherapy for lasting effects.
Research Team
Oneysha Brown, BA
Principal Investigator
Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai
Adriana Feder, MD
Principal Investigator
Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Ketamine
- Written Exposure Therapy
Ketamine is already approved in United States, European Union, Canada for the following indications:
- Anesthesia
- Treatment-resistant depression
- Anesthesia
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor